Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Synopsys, Inc. (SNPS) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance

Synopsys, Inc.Trade
DENTSPLY SIRONA IncTrade

Price performance (Past 24H)

Key statistics

Synopsys, Inc. vs DENTSPLY SIRONA Inc — how do they compare? Synopsys, Inc. trades at $389.5 (market cap $72.47B), while DENTSPLY SIRONA Inc trades at $13.56 (market cap $2.70B). The key difference: Synopsys, Inc. is far larger — about 26.8× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while Synopsys, Inc. pays none. Which is the better fit depends on your goals.

SNPSXRAY
Market Cap
$72.47B$2.70B
Sector
TechnologyHealth
52-Week High
$645.59$16.85
52-Week Low
$378.46$9.64
Enterprise Value
$80.82B$4.84B
Dividend Yield
5.04%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Synopsys, Inc.

Synopsys (SNPS) trades at $388.84, up 1.19% on the day, with a bearish technical signal despite recent earnings beats. The stock faces headwinds from semiconductor sector volatility but maintains strong analyst support with an 82.76% buy rating. Recent news highlights the company's strategic pivot toward AI design tools and margin expansion following its Ansys integration, positioning it as a key enabler in the chip design ecosystem despite near-term price pressure.

Outlook remains positive long-term due to SNPS's dominant EDA market position and AI-driven growth opportunities, though investors face risks from cyclical semiconductor demand and integration execution. The consensus price target of $559.50 implies significant upside if the company delivers on its AI strategy and margin improvements.

DENTSPLY SIRONA Inc

Dentsply Sirona (XRAY) trades at $13.65, down 2.91% on the day, with a mixed technical picture showing a bullish moving average signal but overbought RSI levels. Fundamentally, the company reported a net loss of $598 million for 2025, with negative profit margins and an elevated EV/EBITDA of 91.48, though revenue remains stable near $3.7 billion. Recent news includes the appointment of a new CFO and expanded U.S. distribution partnerships, while the upcoming Q2 2026 earnings call on August 6 is a key near-term catalyst.

The outlook remains challenging due to persistent losses and margin pressure, offset by strategic growth initiatives. Investment opportunities lie in the company's market leadership and digital dentistry expansion, but risks include high debt levels, competitive pressures, and the need for a successful turnaround. Analyst consensus is Hold with a price target of $13.33, indicating limited near-term upside from current levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Synopsys, Inc.

Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.

Read more on SNPS

About DENTSPLY SIRONA Inc

Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters

Read more on XRAY